CAJ | 학술논문

目的探讨类表皮生长因子域7(epidermal growth factor-like domain 7,egfl 7)在动脉硬化闭塞症(arteriosclerosis obliterans,ASO)和腹主动脉瘤(abdominal aortic aneurysm,AAA)中的表达特点及其在动脉粥样硬化(atherosclerosis,AS)发病过程中的作用.方法收集正常动脉8例,下肢ASO标本11例,AAA标本34例,应用免疫组织化学技术和原位杂交技术检测egfl7蛋白和egfl7mRNA.应用qRT-PCR技术检测egfl 7 mRNA的表达水平.应用RNA干扰技术检测egfl 7的作用.结果在ASO和AAA中,egfl 7蛋白主要表达于动脉中膜;egfl7 mRNA的表达部位与egfl 7蛋白一致.在ASO早期、AAA与正常动脉相比,egfl 7 mRNA的表达水平显著上调(325%±120%比100%±36%.P＜0.01,216%±133%比100%±36%,P＜0.05).干扰egfl 7后,平滑肌细胞(smooth muscle cells,SMCs)的增殖能力与对照组相比明显降低(0.85±0.05比1.34±0.04,P＜0.01),吸光度值降低(0.85±0.05比1.32±0.09,P＜0.01).结论 egfl 7可能是调控AS发病过程的一个重要基因,可能通过促进血管平滑肌细胞的增殖起作用,是早期ASO的标志.
목적 탐토류표피생장인자역7(epidermal growth factor-like domain 7,egfl 7)재동맥경화폐새증(arteriosclerosis obliterans,ASO)화복주동맥류(abdominal aortic aneurysm,AAA)중적표체특점급기재동맥죽양경화(atherosclerosis,AS)발병과정중적작용.방법수집정상동맥8례,하지ASO표본11례,AAA표본34례,응용면역조직화학기술화원위잡교기술검측egfl7단백화egfl7mRNA.응용qRT-PCR기술검측egfl 7 mRNA적표체수평.응용RNA간우기술검측egfl 7적작용.결과 재ASO화AAA중,egfl 7단백주요표체우동맥중막;egfl7 mRNA적표체부위여egfl 7단백일치.재ASO조기、AAA여정상동맥상비,egfl 7 mRNA적표체수평현저상조(325%±120%비100%±36%.P＜0.01,216%±133%비100%±36%,P＜0.05).간우egfl 7후,평활기세포(smooth muscle cells,SMCs)적증식능력여대조조상비명현강저(0.85±0.05비1.34±0.04,P＜0.01),흡광도치강저(0.85±0.05비1.32±0.09,P＜0.01).결론 egfl 7가능시조공AS발병과정적일개중요기인,가능통과촉진혈관평활기세포적증식기작용,시조기ASO적표지.
Objective To investigate the expression characteristics of epidermal growth factor-like domain 7 ( egfl 7 ) in arteriosclerosis obliterans ( ASO) tissues and abdominal aortic aneurysm ( AAA ) tissues, and it's role in atherosclerosis (AS).Methods In this study, 8 normal artery, 11 lower extremity ASO and 34 AAA samples were collected.Immunohistochemistry and in situ hybridization were performed in artery sections to investigate the expression characteristics of egfl 7 at protein and mRNA levels.The relative quantitative detection of egfl 7 mRNA was detected by qRT-PCR.The effect of egfl 7 was examined by RNA interference.Results In ASO and AAA samples, the expression of egfl 7 protein was mainly in the tunica media; The expression site of egfl 7 mRNA was the same as that of egfl 7 protein.Compared with normal artery samples, the expression of egfl 7 mRNA was significantly upregulated in the early stage of ASO samples and AAA samples (325 ± 120 vs.100 ± 36, P ＜ 0.01, 216 ± 133 vs.100 ± 36, P ＜ 0.05 ).Compared with the control group, the proliferative ability of smooth muscle cells was significantly down regulated after egfl 7 interference (0.85 ± 0.05 vs.1.34 ± 0.04, P ＜ 0.01).Conclusions egfl 7 might be a gene that regulates the pathogenic process of atherosclerosis through promoting vascular smooth muscle cell proliferation.